NJ-ZYCUS
4.4.2024 17:01:26 CEST | Business Wire | Press release
Zycus, a global leader in cognitive procurement technology solutions, set another new milestone by announcing integration with Microsoft Azure OpenAI Service. This integration is a step towards an ongoing effort to build the world’s first generative AI powered S2P platform. This continuous engagement will harness the power of advanced AI to transform end to end source to pay processes, offering unprecedented efficiency, compliance, and ease of use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401357521/en/
Zycus launched world's first Generative AI powered S2P platform in collaboration with Microsoft (Graphic: Business Wire)
Zycus has already incorporated various Generative AI capabilities in the existing S2P Suite under the Merlin Assist offering. It is available both through an App published on Microsoft Teams and via Zycus web app.
“We are thrilled to partner with Microsoft. Many of our clients, global enterprises from across the world, have deployed Merlin Assist as part of our early access program and share very encouraging feedback on ease of use, compliance, and productivity. We are certain that sourcing & procurement will be fundamentally transformed in the months to come,” said Aatish Dedhia, Founder & CEO of Zycus.
Samik Roy, Executive Director, Corporate Medium and Small Businesses, Microsoft India said, “AI will transform the way individuals, teams and organizations work. Zycus has integrated Azure OpenAI to infuse AI into its S2P Platform. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus’ customers’ success.”
Some top use cases of Generative AI are enhancing the complete S2P process:
1. Efficiency and Time-Saving Innovations:
Harnessing the power of Azure OpenAI Service, Zycus can enhance the end-to-end procurement lifecycle, starting from swift recommendations of alternate suppliers to simplifying contract management with abstract language contract processing. Zycus has also built autoscore RFP capability that accelerates proposal evaluations. These innovations reduce manual efforts, saving valuable time and minimizing errors.
2. Enhanced Source Aggregation and Risk Assessment:
Zycus users are empowered with powerful source aggregation and tracking, combined with robust risk assessment. Azure OpenAI Service’s advanced algorithms process thousands of articles daily delivering a fourfold boost in article processing throughput. iRisk generates compliance-related questionnaires, easing the assessment process while offering strategic suggestions for mitigating identified risks. This approach streamlines compliance processes and delivers actionable strategies for enhanced predictive risk management.
3. Democratized Procurement via Microsoft Teams:
Zycus has seamlessly integrated its platform with Microsoft Teams to boost adoption. This integration makes procurement accessible to everyone. From policy adherence, extracting contract line items to comprehensive supplier response summaries and RFQ (Request For Quotation) questionnaire generation, all the features are built to continuously enhance user experience and get maximum ROI from the platform.
4. Precision-Driven AI Models for Informed Decisions:
The integration ensures more accurate, data-driven insights on alternative items, PR/PO summaries, and price trends, facilitating smarter purchasing choices procurement decisions, minimizing risks and optimizing outcomes.
“By combining the strengths of Azure OpenAI with Zycus’ native source to pay platform, we are setting a new standard in the industry. Our clients can now experience enhanced efficiency, risk management, and user engagement, driving procurement transformation at scale,” said Aatish Dedhia.
About Zycus
Zycus is a leading global provider of end-to-end Source to Pay solutions, pioneering in the space of cognitive procurement, powered by its advanced Merlin AI Suite. With a strong emphasis on transforming the procurement landscape, Zycus leverages Generative AI to offer innovative, AI-driven capabilities that streamline procurement processes, enhance decision-making, and foster strategic sourcing and supplier management.
To see the Microsoft and Zycus integrated platform in action, join us on April 9, 1 PM - 2:30 PM ET.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401357521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
